These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.
    Author: Rolston K, Ho DH, LeBlanc B, Bodey GP.
    Journal: Chemotherapy; 1988; 34(6):448-54. PubMed ID: 3149568.
    Abstract:
    The in vitro activity of Fleroxacin (Ro23-6240; AM 833), a new fluorinated 4-quinolone, was compared to that of ciprofloxacin, enoxacin and A-56620, against 747 isolates from cancer patients. Fleroxacin inhibited more than 90% of Enterobacteriacea isolates at a concentration of less than or equal to 0.25 micrograms/ml. It was also extremely active against Aeromonas hydrophila and Haemophilus influenzae isolates with MIC90 values of 0.12 and 0.06 micrograms/ml, respectively. The MIC90 for Acinetobacter spp. was 1.0 micrograms/ml, for Pseudomonas aeruginosa and Pseudomonas fluorescens 4.0 micrograms/ml, and for other Pseudomonas spp., 8.0 micrograms/ml. Staphylococcus aureus isolates including methicillin-resistant strains were inhibited by less than or equal to 1.0 microgram/ml. The MIC90 for three different species of coagulase-negative Staphylococci was 1.0 microgram/ml. Streptococcal species required 8-16 micrograms/ml for inhibition. Fleroxacin was also active against group JK-diphtheroids and Bacillus cereus. The overall activity of fleroxacin was similar to that of enoxacin and less than that of A-56620 and ciprofloxacin.
    [Abstract] [Full Text] [Related] [New Search]